Last reviewed · How we verify
emtricitabine [FTC]/tenofovir [TDF]
This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.
This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).
At a glance
| Generic name | emtricitabine [FTC]/tenofovir [TDF] |
|---|---|
| Sponsor | Tibotec, Inc |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Emtricitabine and tenofovir are both nucleoside/nucleotide analogs that inhibit HIV reverse transcriptase, the enzyme the virus uses to convert its RNA genome into DNA for integration into host cells. By blocking this critical step in the HIV replication cycle, the combination reduces viral load and slows disease progression. This fixed-dose combination is commonly used as part of antiretroviral therapy regimens.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
- HIV-1 pre-exposure prophylaxis (PrEP)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Lactic acidosis (rare but serious)
- Hepatotoxicity
- Renal impairment (tenofovir-related)
- Bone density loss
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- emtricitabine [FTC]/tenofovir [TDF] CI brief — competitive landscape report
- emtricitabine [FTC]/tenofovir [TDF] updates RSS · CI watch RSS
- Tibotec, Inc portfolio CI